Carrier Screening for Genetic Diseases
Customize your policy alerts
Sign up for all blue cross blue shield - kansas policy alerts
Know when blue cross blue shield - kansas releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs medical necessity and coverage criteria for targeted risk-based and non-targeted carrier screening for autosomal recessive and X-linked single-gene disorders in individuals who are pregnant or considering pregnancy. It applies to providers and members covered by Blue Cross and Blue Shield of Kansas.
No material clinical or coverage changes in this revision.
Coverage Criteria for Carrier Screening
Targeted Risk-Based Carrier Screening (Medically Necessary)
Covered when ONE of (a-c) is met AND ALL of (d-i) are met
Non-Targeted Carrier Screening (Medically Necessary Alternative)
Covered when ALL of the following are met
Appropriate indications for carrier screening
Covered when testing meets clinical validity and intended use standards
ACOG accepts ethnic-specific, panethnic, and expanded strategies; ACMG provides a multi-tier approach
Definitions of elevated risk listed in policy
Coverage rationale and clinical utility
Clinical utility and coverage considerations center on the ability of carrier screening to affect reproductive decisions and identify carriers of severe conditions; evidence is primarily observational or modeling-based.
Supported by observational studies and modeling showing interventions and potential impact
Action rates vary with disease severity
ACOG notes expanded screening does not replace risk-based screening; ACMG provides tiered recommendations
Expanded Carrier Screening - Example Criteria
Example expanded carrier screening panel content adapted from ACOG Committee Opinion No. 690 (2017, reaffirmed 2023):
See Appendix Table 2 for condition-specific frequencies and ethnic‑group notes (e.g., Tay–Sachs DNA testing limitations).
Any targeted or non-targeted carrier screening that does not meet the specific medical necessity criteria listed for Targeted Risk‑Based or Non‑Targeted carrier screening is considered experimental/investigational and is not covered. (See the policy sections that define required clinical validity, disease severity, and prior testing conditions.)
Some genes included on large expanded carrier panels do not meet prevalence or well‑defined phenotype/severity criteria (for example, carrier rate thresholds referenced by professional guidance). Such genes may be excluded from routine coverage when they fail to meet guideline thresholds for carrier frequency or phenotype clarity.
Expanded carrier screening panels may not provide the most sensitive method for detecting carrier status for certain conditions. ACOG specifically notes that some molecular panels can be less sensitive than condition‑specific approaches (for example, hemoglobinopathy screening and Tay‑Sachs), and therefore panel results should be interpreted in the context of condition‑specific recommendations.
For Tay‑Sachs disease, molecular (DNA) testing alone can miss up to 10% of carriers, particularly in low‑risk populations. In these circumstances, hexosaminidase A enzyme testing on blood may be the more appropriate screening method to identify carriers across ethnic groups.
Carrier screening (targeted or non‑targeted) is generally considered medically necessary once per lifetime. Repeat testing is not routinely covered unless new technology or clinically justified changes make retesting medically necessary.
When a test or panel lacks demonstrated clinical validity (that is, the test does not reliably detect the presence/absence of relevant pathogenic variants or the pathogenicity/penetrance is not defined), clinical utility cannot be inferred and the test is not considered medically necessary.
Procedure, diagnosis, and device codes listed in this policy are provided for informational purposes only. Inclusion of a code does not by itself establish coverage; services are medically necessary only when performed in accordance with the policy's medical necessity criteria and the member's contract.
Covered Indications
Preconception or prenatal screening to identify carrier status in asymptomatic prospective or expectant parents
Preconception and prenatal carrier screening to inform reproductive decision making
Preconception or prenatal carrier screening to assess reproductive risk
Eligibility Requirements
A first‑ or second‑degree relative affected by an X‑linked or autosomal recessive condition qualifies as an indication for targeted (risk‑based) carrier screening. The policy defines first‑degree relatives as a biological parent, brother, sister, or child; second‑degree relatives include biological grandparents, aunts, uncles, nieces, nephews, grandchildren, and half‑siblings.
A documented first‑ or second‑degree relative affected by the condition of interest meets the policy's family‑history trigger for targeted carrier screening and supports medical necessity when combined with the additional required criteria in the policy.
The presence of an affected first‑ or second‑degree relative is explicitly recognized as an indication supporting targeted carrier screening under the policy's eligibility requirements.
Provider Actions, Documentation, and Billing
Bill panels with appropriate panel CPT (eg, 81443) when composition rules met
Certain non-targeted or expanded carrier screening panels that meet the policy's panel composition rules (including inclusion of CFTR and SMN1) should be billed using the appropriate panel CPT code (for example, 81443) rather than unbundling individual gene codes.
Confirm panel/genes meet clinical‑validity and guideline criteria during authorization
Prior authorization reviews should confirm that the selected panel or genes align with clinical validity and guideline criteria (for example, carrier frequency thresholds and well‑defined phenotype), and that panethnic rationale is documented when ethnicity‑based testing is not used.
- Ensure panel content meets ACOG/ACMG clinical validity expectations (eg, carrier frequency ≥1/100 and well-defined phenotype).
- Document rationale for panethnic testing if ethnicity-based testing is not the basis for selection.
Listed CPT/HCPCS codes apply only when tests meet policy medical‑necessity criteria
The CPT/HCPCS codes listed in the policy (examples include 81412, 81443, 0400U) are included as codes applicable to tests governed by this policy; coverage of procedures is subject to meeting the policy's medical necessity criteria and the member's contract.
- Listed codes are informational and are medically necessary only when the procedure is performed according to the Policy section.
Obtain prior authorization when payer requires it for listed carrier screening CPTs
Providers should check payer prior authorization rules and obtain prior authorization for listed carrier screening CPT codes when required by the payer.
- Prior authorization requirements may apply to common panel codes (eg, 81443) and other listed CPTs; obtain authorization per payer rules before testing.
Prefer targeted partner testing after proband testing
After testing the proband, perform targeted testing on the reproductive partner first rather than immediately ordering a broader non‑targeted panel for the partner.
- Testing of the partner should be limited to genes meeting the criteria; broader testing on the partner is not preferred unless clinically indicated.
Consider targeted (risk‑based) screening before larger non‑targeted panels
Consider targeted (risk‑based) carrier screening as the initial comparator because larger non‑targeted panels increase downstream partner testing, counseling needs, and costs.
- Use targeted screening as the comparator when evaluating need for broader panels.
- Recognize that larger panels increase the likelihood of identifying carriers and the need for follow-up.
Do not replace risk‑based screening—establish a consistent offering per ACOG
Follow ACOG guidance that expanded carrier screening does not replace previous risk‑based screening recommendations; providers should establish and consistently offer a standard approach after counseling.
- Ensure that expanded screening is implemented alongside, not as a replacement for, recommended condition‑specific risk‑based screening.
- Establish a consistent practice approach to offering carrier screening to patients.
Use panels that include CFTR and SMN1 for targeted testing and document prior testing
Panels used to perform targeted testing must include CFTR and SMN1 when billed as the referenced panel codes, and prior carrier screening history must be documented because previous testing for the gene variants of interest precludes coverage.
- If targeted testing is performed by a panel, the panel and panel billing code should include CFTR and SMN1.
- Document prior carrier screening history—previous testing for the same gene variants disqualifies repeat coverage.
Document testing purpose and intended use with guideline rationale
Clinical documentation must state the testing purpose (preconception or prenatal carrier screening) and show that results will be used to inform reproductive decisions; cite guideline rationale (ACOG/ACMG) when relevant.
- Indicate whether testing is preconception or prenatal and how results will inform reproductive management.
- Reference guideline support (eg, ACOG, ACMG) when using expanded or panethnic approaches.
Require lab reports to specify panel content, ACMG tier, method, and variant reporting limits
Laboratory reports should describe panel content and corresponding ACMG tier, state the testing approach and detectable variant types, and report only pathogenic/likely pathogenic variants (VUS reporting only in partners of identified carriers with consent).
- Report panel content and ACMG tier on the laboratory report.
- Clearly state testing approach and variant types detected; limit reports to pathogenic/likely pathogenic variants unless VUS reporting is consented and limited to partner testing.
Include supporting ICD‑10 diagnosis codes indicating carrier screening context on claims
Include diagnosis codes on claims that support carrier screening (examples: O09, Z13, Z31, Z34, Z36, Z84) and indicate the reproductive or preconception/pregnancy context.
- Use appropriate ICD‑10 codes (eg, O09, Z13, Z31, Z34, Z36, Z84) to document carrier screening context on the claim.
Targeted screening not meeting medical‑necessity criteria will be denied
Targeted carrier screening that does not meet the policy's listed medical‑necessity criteria is considered experimental/investigational and will be denied.
- Ensure targeted testing meets all listed criteria (one of a–c and all of d–i) to avoid denial.
Non‑targeted panels not meeting policy criteria will be denied
Non‑targeted carrier screening panels that do not meet the policy's specified criteria are considered experimental/investigational and will be denied.
- Verify that all non‑targeted panel criteria (a–f) are met before ordering to prevent denial.
Require clinical validity (eg, ACOG carrier frequency and phenotype criteria) for covered tests
Tests must demonstrate clinical validity for included genes—examples include meeting ACOG criteria such as carrier frequency ≥1/100 and well‑defined phenotype; lack of demonstrated clinical validity may be a basis for noncoverage or denial.
- Confirm included genes meet clinical validity expectations (carrier frequency thresholds, defined phenotype, severity).
Code listing does not imply coverage or reimbursement—verify policy and member contract
Inclusion of codes in this policy is informational only and does not guarantee member coverage or provider reimbursement; listed codes are medically necessary only if the procedure is performed according to the Policy section.
- Always verify member contract benefits and that the procedure meets the Policy section before billing.
Avoid CPT/ICD code mismatches to reduce risk of claim issues or denials
Using CPT codes that are inconsistent with the policy's listed carrier‑screening codes or failing to include appropriate ICD‑10 carrier/screening diagnosis codes (examples: O09, Z13, Z31, Z34, Z36, Z84) may trigger claim issues or denials.
Recommend formal genetic counseling by experienced personnel before carrier screening
Formal genetic counseling is recommended in most cases when genetic testing for an inherited condition is considered and should be performed by someone with experience in genetic medicine; carrier screening should be performed in adults with appropriate counseling.
- Genetic counseling should be offered prior to testing and be delivered by personnel with expertise in genetic medicine.
- Carrier screening is intended for adults and should be accompanied by counseling to support informed decision‑making.
Offer counseling and allow patients to decline screening per ACOG—establish standard approach
ACOG recommends counseling and that after counseling a patient may decline any or all carrier screening; providers should establish a standard approach that is consistently offered to each patient.
- Offer counseling and document the discussion; respect patient choice to decline screening after counseling.
Perform carrier screening only in adults with pretest genetic counseling
Carrier screening should be performed only in adults, and pretest genetic counseling by experienced personnel is recommended.
- Ensure the individual is an adult and that pretest counseling is provided or documented.
Appropriate clinicians (OB/GYN, family practice, genetics, counselors) may order carrier screening
Tests in the evidence base were ordered by a variety of clinicians including obstetricians/gynecologists, family practitioners, geneticists, genetic counselors, perinatologists, and reproductive endocrinologists; ordering by appropriate clinicians is implied.
- Ensure ordering clinician is appropriate for reproductive genetic screening in your practice setting.
Establish and consistently offer a standard carrier‑screening approach (document offering)
Providers should establish and consistently offer a standard carrier‑screening approach (eg, offer Tier 3 per ACMG or follow ACOG recommendations) and document that the approach was offered and discussed with each patient.
- Document that a standard approach to offering carrier screening was provided and discussed, ideally before pregnancy.
- Consider ACMG Tier recommendations when establishing practice standards.
(No additional provider action specified)
This block placeholder is intentionally left empty.
Coding and Billing References
| 81443 | Unlisted multi-gene panel code referenced for panels of certain sizes including CFTR and SMN1 |
| 81412 | Ashkenazi Jewish associated disorders, genomic sequence analysis panel, must include sequencing of at least 9 genes (examples listed). |
| 81443 | Genetic testing for severe inherited conditions, genomic sequence analysis panel, must include sequencing of at least 15 genes (examples listed). |
| 0400U | Obstetrics (expanded carrier screening), 145 genes by next generation sequencing, fragment analysis and MLPA, DNA, reported as carrier positive or negative |
| 81443 | Expanded carrier screening panel |
| 81412 | Ashkenazi Jewish carrier panel |
| 81220 | CFTR testing (cystic fibrosis) |
| 81161 | DMD deletion/duplication analysis |
| 81255 | HEXA targeted mutation analysis (Tay-Sachs) |
| O09 | Supervision of high-risk pregnancy (used as example ICD-10) |
| Z13 | Encounter for screening for other diseases and disorders |
| Z31 | Encounter for procreative genetic counseling and screening |
| Z34 | Encounter for supervision of normal pregnancy |
| Z36 | Encounter for antenatal screening of mother |
| Z84 | Family history of genetic and other congenital anomalies |
Not Covered / Experimental
Targeted or non‑targeted carrier screening that does not meet the policy's specified medical necessity criteria — including clinical validity, disease severity, panel composition rules, and prior testing requirements — is considered experimental/investigational and not covered.
Genes on expanded panels that lack demonstrated prevalence (for example, not meeting carrier frequency thresholds referenced by professional guidance) or that lack a clear, well‑defined phenotype/severity may be excluded from routine coverage decisions.
Some molecular expanded panels are inadequate for conditions where specific assays are recommended. For example, hemoglobinopathy screening requires hematologic testing (MCV and hemoglobin electrophoresis) and Tay‑Sachs carrier status is best identified by enzyme analysis in some populations rather than by molecular panels alone.
Background
Carrier screening is intended to identify asymptomatic individuals who are heterozygous for autosomal recessive or X‑linked single‑gene disorders in order to determine the risk of conceiving an affected child. It may be performed before conception or during pregnancy to inform reproductive decision making and to guide partner testing and counseling.
Definitions and Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.